Advaxis’ Preclinical Neoantigen Technology (ADXS-NEO)

Description: Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and Advaxis that is designed to activate a patient's immune system to respond to certain mutations in the tumors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Shared By : AnnualMeeting2017
Posted on : 06/14/17
Added : 2 years ago
Category : Other